Why the study?
What are the pharmacokinetics of a single dose of valsartan oral suspension in pediatric and adolescent subjects with hypertension?
What are the pharmacokinetics of a single dose of valsartan oral suspension in pediatric and adolescent subjects with hypertension?
Valsartan oral suspension exhibits comparable dose- and weight-normalized pharmacokinetic parameters across pediatric age groups from 1 to 16 years.
Answers are grounded in this paper and cite their sources.
Supports similar exposure with valsartan suspension across ages 1-16; leaves open randomized efficacy trials before uniform dosing adoption.
An open-label, single-dose study is conducted in 26 children with hypertension to characterize the pharmacokinetics of valsartan. Valsartan is administered as an oral suspension (dose of 2 mg/kg), with the maximum single dose being 80 mg. Subjects are stratified into 4 age categories: group 1, 1 to less than 4 years; group 2, 4 to less than 6 years; group 3, 6 to less than 12 years; group 4, 12 to 16 years. Blood samples are collected before and for 24 hours after dosing to quantitate valsartan. Because the body weight of most children in groups 3 and 4 exceeds 40 kg and they received a dose of less than 2 mg/kg, major pharmacokinetic parameters are dose normalized for comparison across the age groups. Dose-normalized maximum plasma concentration and area under the plasma-concentration curve and body weight-normalized apparent oral clearance are comparable for the 4 groups (P > or = .1011). Body weight-normalized apparent oral clearance ranges from 0.061 to 0.089 L/h/kg.
No takes yet. Share an insight, caveat, or question.
Blumer et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: